Health Care · Pharmaceutical Preparations · NYSE · CIK 1894525 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $5.75Day −28.13%Mkt cap $87M1Y −96.9%Off 52W high −98.6%Vol (1Y) 176.1%
Daily closing price, split-adjusted to the current basis; 1.2y shown of 295 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest1.2% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)+0.06% |
| Top-10 13F concentration100.0% |
| Next report (est.)2026-08-22 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$40.7M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−96.5% |
| 1Y−96.9% |
| Since incept. (ann.)−94.9% |
Total return through 2026-07-29 · series begins 2025-05-09. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)176.1% |
| Ann. volatility (3Y)163.3% |
| Sharpe (1Y)−0.64 |
| Sharpe (3Y)−0.56 |
| Max drawdown (1Y)−98.5% |
| Max drawdown (3Y)−98.5% |
| Beta (3Y vs SPY)4.87 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Hemenway Trust Co LLC | 274,000 | $490,296 | 1.82% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 95,929 | $171,617 | 0.64% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 40,051 | $71,666 | 0.27% | +14.8% |
| VANGUARD FIDUCIARY TRUST CO | 24,039 | $43,006 | 0.16% | new |
| TWO SIGMA SECURITIES, LLC | 10,550 | $18,878 | 0.07% | new |
| UBS Group AG | 4,187 | $7,491 | 0.03% | +619.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-26 | — | — | — | — |
| 2025-09-30 | 2025-11-12 | — | — | — | — |
| 2025-06-30 | 2025-08-19 | — | — | — | — |
| 2025-03-31 | 2025-05-20 | — | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-22 is ESTIMATED from filing cadence (median gap 88d) — not company-confirmed.
